Company / Free Cash Flow
X4 Pharmaceuticals, Inc Free Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$96.6M
FY2025
5-year range
-$96.6M / -$25.4M
FY2021-FY2025
Trend
-25.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has declined for 5 consecutive years, from -$22M in FY2018 to -$97M in FY2025.
Based on SEC 10-K filings.
-$97M in FY2025.
Declined from -$60M to -$97M over the past 3 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- X4 Pharmaceuticals, Inc's free cash flow has declined for 5 consecutive years.
- In FY2025, free cash flow decreased 25.1% year-over-year.
- Peak free cash flow was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -0.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$96.6M | -25.1% |
| FY2024 | -$77.2M | -28.3% |
| FY2022 | -$60.2M | -24.8% |
| FY2021 | -$48.2M | -89.7% |
| FY2020 | -$25.4M | -17.1% |
| FY2018 | -$21.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026